121341-81-9
121341-81-9 結(jié)構(gòu)式
基本信息
H-ALA-GLY-TYR-LYS-PRO-ASP-GLU-GLY-LYS-ARG-GLY-ASP-ALA-CYS-GLU-GLY-ASP-SER-GLY-GLY-PRO-PHE-VAL-OH
物理化學(xué)性質(zhì)
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2023/03/20 | HY-P0316 | TP 508 TP508 | 121341-81-9 | 1mg | 1200元 |
| 2023/03/20 | HY-P0316 | TP 508 TP508 | 121341-81-9 | 5mg | 4800元 |
常見(jiàn)問(wèn)題列表
TP508 (50 μg/mL; 24 hours; HCAEC) treatment reverses radiation-induced endothelial dysfunction (ED) and loss of NO signaling by attenuating the downregulation of eNOS expression. TP508 treatment is able to stimulate NO production in the irradiated cells.
TP508 mitigates effects of nuclear radiation on human endothelial cells in culture restoring endothelial NO production, tube formation and accelerating repair of radiation-induced DNA double-strand breaks (DSB).
TP508 acts as an antagonist for the effects of thrombin. TP508 peptide inhibits these thrombin-induced effects through a RGD and αvβ3-related mechanism.
Western Blot Analysis
| Cell Line: | Primary human coronary artery endothelial cells (HCAEC) |
| Concentration: | 50 μg/mL |
| Incubation Time: | 24 hours |
| Result: | Prevented the radiation-induced downregulation of eNOS. |
TP508 (10 mg/kg; intravenous injection; male CD-1 mice) treatment mitigates radiation-induced endothelial cell damage, also significantly increases survival of CD-1 mice when injected 24 h after 8.5 Gy exposure.
| Animal Model: | Male CD-1 mice (12-15-week old) with γ irradiation |
| Dosage: | 10 mg/kg |
| Administration: | Intravenous injection |
| Result: | Mitigated radiation-induced endothelial cell damage, also significantly increased survival of CD-1 mice. |